STIM · Neuronetics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | FY 2024 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $34.45M | - | $37.30M | $38.11M | $31.98M | - | $18.53M | - | $16.45M | $17.42M |
| Cost of Revenue | $18.30M | - | $20.19M | $20.35M | $16.24M | - | $4.53M | $20.58M | $4.27M | $4.33M |
| Gross Profit | $16.15M | - | $17.11M | $17.76M | $15.74M | - | $14.00M | - | $12.18M | $13.09M |
| R&D | $1.36M | - | $1.50M | $1.80M | $1.62M | - | $2.42M | - | $2.23M | $2.35M |
| SG&A | $13.05M | - | $11.08M | $12.15M | $13.14M | - | $7.44M | $6.29M | $6.15M | $5.96M |
| Total Operating Expenses | $25.15M | - | $24.43M | $25.82M | $26.75M | - | $21.73M | - | $20.69M | $19.95M |
| D&A | $745.0K | - | $500.0K | $500.0K | $911.0K | - | $500.0K | - | $600.0K | $560.0K |
| Operating Income | ($8.99M) | - | ($7.32M) | ($8.06M) | ($11.01M) | - | ($7.73M) | ($12.88M) | ($8.51M) | ($6.86M) |
| Interest Expense | $2.27M | - | $2.21M | $1.97M | $1.92M | - | $1.73M | - | $1.98M | $1.83M |
| Income Tax | - | - | - | - | - | - | - | $0 | - | - |
| Net Income | ($10.79M) | - | ($9.04M) | ($10.12M) | ($12.68M) | - | ($13.34M) | ($13.21M) | ($9.83M) | ($7.87M) |
| EPS - Basic | ($0.16) | - | ($0.13) | ($0.15) | ($0.21) | - | ($0.44) | - | ($0.33) | ($0.27) |
| EPS - Diluted | ($0.16) | - | ($0.13) | ($0.15) | ($0.21) | - | ($0.44) | - | ($0.33) | ($0.27) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | FY 2024 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $13.21M | $28.13M | $27.97M | $10.97M | $20.22M | $18.46M | $20.87M | - | $42.64M | $47.73M |
| Accounts Receivable | $15.81M | $16.47M | $18.69M | $26.12M | $26.20M | $23.36M | $16.82M | - | $17.14M | $17.50M |
| Inventory | $4.71M | $4.33M | $4.32M | $4.94M | $4.07M | $4.25M | $4.96M | - | $6.14M | $6.69M |
| Accounts Payable | $11.43M | $10.74M | $11.57M | $9.72M | $8.48M | $11.08M | $3.29M | - | $4.10M | $2.98M |
| Current Assets | $47.17M | $61.55M | $64.89M | $56.14M | $60.67M | $58.12M | $53.46M | - | $75.51M | $81.86M |
| Total Assets | $125.44M | $141.55M | $145.47M | $134.65M | $141.99M | $140.90M | $74.12M | - | $96.81M | $103.81M |
| Current Liabilities | $28.29M | $30.52M | $28.94M | $27.80M | $24.84M | $31.27M | $16.90M | - | $29.26M | $14.50M |
| Long-term Debt | $61.30M | $65.81M | $65.67M | $55.54M | $55.34M | $55.15M | $46.00M | - | $46.15M | $59.44M |
| Total Liabilities | $108.38M | $115.31M | $114.11M | $103.14M | $102.46M | $109.10M | $64.74M | - | $77.43M | $76.16M |
| Stockholders' Equity | $13.27M | $22.38M | $27.36M | $27.15M | $35.45M | $27.71M | $9.38M | - | $19.39M | $27.66M |
| Retained Earnings | ($469.58M) | ($458.79M) | ($451.63M) | ($442.58M) | ($432.46M) | ($419.79M) | ($407.13M) | - | ($393.79M) | ($383.95M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | FY 2024 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($9.42M) | - | - | - | ($16.99M) | - | - | - | - | ($12.02M) |
| Investing Cash Flow | ($172.0K) | - | - | - | ($219.0K) | - | - | - | - | $68.0K |
| Financing Cash Flow | ($5.58M) | - | - | - | $18.98M | - | - | - | - | - |
| CapEx | $197.0K | - | - | - | $219.0K | - | - | - | - | $375.0K |
| Free Cash Flow | ($9.62M) | - | - | - | ($17.21M) | - | - | - | - | ($12.39M) |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | FY 2024 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 46.9% | - | 45.9% | 46.6% | 49.2% | - | 75.6% | - | 74.0% | 75.1% |
| Operating margin | -26.1% | - | -19.6% | -21.1% | -34.4% | - | -41.7% | - | -51.7% | -39.4% |
| EBITDA margin | -23.9% | - | -18.3% | -19.8% | -31.6% | - | -39.0% | - | -48.1% | -36.2% |
| Net margin | -31.3% | - | -24.3% | -26.6% | -39.6% | - | -72.0% | - | -59.8% | -45.2% |
| Free cash flow margin | -27.9% | - | - | - | -53.8% | - | - | - | - | -71.1% |
| FCF / Net income | 0.89 | - | - | - | 1.36 | - | - | - | - | 1.57 |
| R&D / Revenue | 4.0% | - | 4.0% | 4.7% | 5.1% | - | 13.0% | - | 13.6% | 13.5% |
| SG&A / Revenue | 37.9% | - | 29.7% | 31.9% | 41.1% | - | 40.1% | - | 37.4% | 34.2% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.6% | - | -6.2% | -7.5% | -8.9% | - | -18.0% | - | -10.2% | -7.6% |
| Return on equity | -81.3% | - | -33.1% | -37.3% | -35.8% | - | -142.2% | - | -50.7% | -28.5% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.67 | 2.02 | 2.24 | 2.02 | 2.44 | 1.86 | 3.16 | - | 2.58 | 5.65 |
| Quick ratio | 1.50 | 1.87 | 2.09 | 1.84 | 2.28 | 1.72 | 2.87 | - | 2.37 | 5.18 |
| Cash ratio | 0.47 | 0.92 | 0.97 | 0.39 | 0.81 | 0.59 | 1.23 | - | 1.46 | 3.29 |
| Leverage | ||||||||||
| Debt / Equity | 4.62 | 2.94 | 2.40 | 2.05 | 1.56 | 1.99 | 4.90 | - | 2.38 | 2.15 |
| Debt / Assets | 0.49 | 0.46 | 0.45 | 0.41 | 0.39 | 0.39 | 0.62 | - | 0.48 | 0.57 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -4.0x | - | -3.3x | -4.1x | -5.7x | - | -4.5x | - | -4.3x | -3.8x |
| Equity multiplier | 9.46 | 6.33 | 5.32 | 4.96 | 4.01 | 5.09 | 7.90 | - | 4.99 | 3.75 |
| Liabilities / Assets | 0.86 | 0.81 | 0.78 | 0.77 | 0.72 | 0.77 | 0.87 | - | 0.80 | 0.73 |
| Efficiency | ||||||||||
| Asset turnover | 0.27 | - | 0.26 | 0.28 | 0.23 | - | 0.25 | - | 0.17 | 0.17 |
| Inventory turnover | 3.88 | - | 4.67 | 4.12 | 3.99 | - | 0.91 | - | 0.70 | 0.65 |
| Days sales outstanding | 167d | - | 183d | 250d | 299d | - | 331d | - | 380d | 367d |
| Days inventory outstanding | 94d | - | 78d | 89d | 91d | - | 400d | - | 525d | 564d |
| Days payable outstanding | 228d | - | 209d | 174d | 191d | - | 266d | - | 351d | 251d |
| Cash conversion cycle | 33d | - | 52d | 164d | 200d | - | 466d | - | 555d | 680d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 7.6x | - | 6.7x | 8.5x | 6.4x | - | 2.5x | - | 2.8x | 5.1x |
| P / S | 2.9x | - | 4.9x | 6.1x | 7.1x | - | 1.2x | - | 3.3x | 8.1x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 7.8% | - | 101.3% | 131.7% | 83.6% | - | 3.6% | - | -6.6% | 12.1% |
| Revenue CAGR (3y) | 30.4% | - | 31.2% | 32.6% | 31.1% | - | 10.3% | - | 5.0% | 12.3% |
| Revenue CAGR (5y) | 22.9% | - | 24.5% | 31.4% | 22.7% | - | 6.2% | - | -0.1% | 11.4% |
| Gross profit growth (YoY) | 2.6% | - | 22.2% | 45.8% | 20.2% | - | 19.0% | - | -4.7% | 14.8% |
| Operating income growth (YoY) | 18.3% | - | 5.3% | 5.3% | -60.6% | - | 12.9% | 5.0% | -15.8% | 30.8% |
| Net income growth (YoY) | 14.9% | - | 32.2% | -2.9% | -61.0% | - | -42.1% | 2.1% | -100.6% | 25.2% |
| EPS growth (YoY) | 23.8% | - | 70.5% | 54.5% | 22.2% | - | -33.3% | - | -94.1% | 28.9% |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 44.1% | - | - | - | -38.9% | - | - | - | - | 19.8% |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -62.6% | -19.2% | 191.6% | 40.0% | 28.2% | -19.0% | -75.3% | - | -57.4% | -42.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$149.16M totalClinical Services Segment$86.98M · 58.3%
Medical Device Segment$62.18M · 41.7%
Product / service
$295.20M totalClinic Revenue$86.98M · 29.5%
Service$86.98M · 29.5%
Product$62.18M · 21.1%
Treatment Sessions$43.32M · 14.7%
Neuro Star Advanced Therapy System$14.26M · 4.8%
Product And Service Other$1.49M · 0.5%
Geographic
$149.16M totalUS$146.05M · 97.9%
Non Us$3.11M · 2.1%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Neuronetics against the 5 most active filers in the same SIC group.